We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study of OV101 in Individuals With Angelman Syndrome (AS) (NEPTUNE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04106557
Recruitment Status : Completed
First Posted : September 27, 2019
Last Update Posted : November 17, 2020
Information provided by (Responsible Party):
Ovid Therapeutics Inc.

Brief Summary:
The purpose of this study is to assess the efficacy and safety of oral OV101 (gaboxadol) in pediatric subjects with Angelman syndrome.

Condition or disease Intervention/treatment Phase
Primary Disease or Condition Being Studied: Angelman Syndrome (AS) Drug: Gaboxadol Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 104 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Masking Description: Double (Participant/Care Giver and Investigator/Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome
Actual Study Start Date : September 9, 2019
Actual Primary Completion Date : November 2, 2020
Actual Study Completion Date : November 2, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: OV101 once daily (weight-based dosing) Other Name:Gaboxadol
OV101 (gaboxadol), oral, provided once daily at bedtime for 12 week duration
Drug: Gaboxadol
OV101 versus placebo once daily at bedtime for 12 weeks

Placebo Comparator: Placebo once daily
Matching placebo,oral, provided once daily at bedtime for 12 week duration
Drug: Placebo
Matching placebo capsules to OV101 capsules.

Primary Outcome Measures :
  1. Clinical Global Impressions- Improvement in Angelman Syndrome (CGI-I-AS) [ Time Frame: 12 weeks ]
    Clinical Global Impressions-Improvement-Angelman Syndrome (CGI-I-AS) - Scale of 1-7 reflects a spectrum where 1 is most improved, 4 is no change, and 7 is most worsened.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female and 2 to 12 years old (inclusive) at the time of informed consent
  • Confirmed molecular diagnosis of AS
  • Has a CGI-S-AS score of 3 or more at baseline.
  • Meets the following age-appropriate body weight criterion:

    1. Subjects 2 to 3 years old must have a minimum body weight of 9 kg.
    2. Subjects 4 years and older must be between 17 kg and 64 kg (inclusive).
  • Stable concomitant mediations for at least 4 weeks before study start

Exclusion Criteria:

  • Any condition that would limit study participation
  • Clinically significant lab or vital sign abnormalities at the time of screening
  • Poorly controlled seizures (weekly seizures of any frequency with a duration more than 3 minutes, weekly seizures occurring more than 3 times per week, each with a duration of less than 3 minutes, or as defined by investigator assessment)
  • Use of prescription medications for sleep, minocycline, or levodopa within the 4 weeks prior to Day 1 or during the study. Benzodiazepines chronically administered for seizure control are permitted.
  • Cannot comply with protocol study assessments during screening or caregiver unable to comply with study requirements.
  • Enrolled in any clinical trial or used any investigational agent within the 30 days before screening or concurrently with this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04106557

Layout table for location information
United States, Arizona
Ovid Therapeutics Investigative Site
Phoenix, Arizona, United States, 85006
United States, California
Ovid Therapeutics Investigative Site
San Diego, California, United States, 92024
United States, Illinois
Ovid Therapeutics Investigative Site
Chicago, Illinois, United States, 60612
United States, Massachusetts
Ovid Therapeutics Investigative Site
Boston, Massachusetts, United States, 02115
Ovid Therapeutics Investigative Site
Lexington, Massachusetts, United States, 02421
United States, Ohio
Ovid Therapeutics Investigative Site
Cincinnati, Ohio, United States, 45229
United States, Pennsylvania
Ovid Therapeutics Investigative Site
Media, Pennsylvania, United States, 19063
United States, Tennessee
Ovid Therapeutics Investigative Site
Nashville, Tennessee, United States, 37232
United States, Washington
Ovid Therapeutics Investigative Site
Tacoma, Washington, United States, 85006
Australia, Queensland
Ovid Therapeutics Investigative Site
Brisbane, Queensland, Australia, 4101
Australia, Victoria
Ovid Therapeutics Investigative Site
Heidelberg, Victoria, Australia, 3084
Ovid Therapeutics Investigative Site
Munich, Germany, 80804
Ovid Therapeutics Investigative Site
Ramat Gan, Israel, 52621
Ovid Therapeutics Investigative Site
Rotterdam, Netherlands, 3012CN
Sponsors and Collaborators
Ovid Therapeutics Inc.
Layout table for additonal information
Responsible Party: Ovid Therapeutics Inc.
ClinicalTrials.gov Identifier: NCT04106557    
Other Study ID Numbers: OV101-19-001
First Posted: September 27, 2019    Key Record Dates
Last Update Posted: November 17, 2020
Last Verified: November 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Angelman Syndrome
Pathologic Processes
Movement Disorders
Central Nervous System Diseases
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
GABA Agonists
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action